{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'remove the efficacy interim analysis after observing 75% of the final OS', 'events and to add a futility analysis at 50% of the final OS events.', 'Rationale: Enable earlier stopping of the trial in the event of. futility and', 'improve statistical properties at final OS.', 'LD SCLC defined in List of Abbreviations as Limited-stage disease small cell', 'lung cancer', 'Rationale: Definition added to clarify the different disease states for SCLC.', 'Modified Section 3.3 Rovalpituzumab Tesirine to provide updated data.', 'Rationale: Latest data added from ongoing Rova-T studies.', 'Modified Section 3.5 Benefits and Risks to update safety language.', 'Rationale: To provide updated safety information', 'Modified Section 5.1 Overall Study Design, Footnote number 3 under Figure 1', \"to include the following updated language- 'Subject is eligible to be\", 'randomized at least 3 but no more than 9 weeks from Day 1 of the fourth cycle', \"of first-line platinum-based chemotherapy.'\", 'Rationale: To be consistent with the update to Inclusion Criteria 5.', 'Modified Section 5.2 Selection of Study Population to include the LD and ED', 'SCLC definition.', 'Rationale: Modified to include the definition per IASLC/VA for LD and ED', 'SCLC.', 'Modified Section 5.2.3.1 Prior therapy to be consistent with changes to', 'Inclusion Criteria 3 and 5.', 'Rationale: To be consistent with the update to Inclusion Criteria 3 and 5.', 'Modified Section 5.2.3.2 Concomitant Therapy to add additional safety', 'guidelines regarding sun exposure.', 'Rationale: To provide updated guidelines regarding sun exposure and to', 'maintain consistent with the Toxicity Management language in Section 6.1.8.2.', 'Modified Section 5.3.1.1 Study Procedures, Vital signs, to address weight', \"increases of 5% or greater and add 'actual' prior to 'weight.'\", 'Rationale: To ensure accurate determination of dose in the event of blinded', 'investigational product-related weight gain due to fluid retention', '4']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Section 5.3.1.1 Study Procedures, Echocardiogram, the following', \"language has been changed: 'Echocardiograms will be performed per\", 'Appendix C, Study Activities to rule out pericardial effusion (or assess, if', 'present), as well as assess cardiac function (left ventricular ejection fraction,', 'LVEF).', 'Rationale: Clarifying the purpose of on-study Echocardiograms.', 'Modified Section 5.3.1.1 Study Procedures, Disease/Response Assessment', '(Radiographic Imaging), language has been added to advise sites on the need', 'to discuss with TA MD regarding the gaps between tumor assessments and', 'doses in certain cases of dose delays.', 'Rationale: Modified to address the planning of CTs in cases of treatment', 'delays.', 'Modified Section 5.3.1.1 Study Procedures, MRI/CT of the Brain and Footnote', 't under Appendix C to clarify that the MRI/CT of the brain is required at', 'screening and when clinically indicated thereafter.', 'Rationale: Modified to clarify when MRI/CT of the brain is required on study.', 'Modified Section 5.3.1.1 Study Procedures, Fluid Retention Questionnaire', '(Including Subject Daily Weight), the following language has been added:', \"'The site will advise subjects to contact the site in cases where sudden weight\", \"gain (5% or greater) is observed for possible assessment in the clinic.'\", 'Rationale: Modified to clarify the definition of weight gain that requires', 'additional assessment by the site.', 'Modified Section 5.3.1.1 Study Procedures, End of Treatment (EOT) Visit, the', \"following language has been added: 'The EOT procedures should be done\", 'within 7 days of documented decision to discontinue treatment and prior to', \"subjects beginning any new anti-cancer therapy if possible.'\", 'Rationale: Modified to fix conflicted language in the protocol.', \"Modified Section 5.3.3.2 Primary Variables to add' determined by a Central\", 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall', \"survival (OS) in DLL3high population.'\", 'Rationale: To clarify the version of RECIST used for this study and to clarify', 'that the DLL3high subjects are analyzed.', '5']\n\n###\n\n", "completion": "END"}